SCHEMBL66633

SCHEMBL66633

O=C(N[C@@H]1CC[C@H]2CN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)C[C@H]21)C(C1CCCCC1)C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.55
CACNA1B Q00975 4/20 0.55
CYP3A4 P08684 4/20 0.45
CYP2D6 P10635 4/20 0.45
TSHR P16473 3/20 0.45
MAPK1 P28482 2/20 0.45
MTOR P42345 2/20 0.45
RAB9A P51151 2/20 0.45
FAAH O00519 1/20 0.45
ALOX12 P18054 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
BLM P54132 2/20 0.44
PMP22 Q01453 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
SCN5A Q14524 2/20 0.42
HTR2A P28223 6/20 0.42
ADRA1A P35348 6/20 0.42
HRH1 P35367 6/20 0.42
DRD3 P35462 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66793 0.96 KCNH2 (0.54) KCNH2CACNA1BCYP3A4CYP2D6TSHR
SCHEMBL65634 0.96 KCNH2 (0.54) KCNH2CACNA1BCYP3A4CYP2D6TSHR
SCHEMBL66732 0.94 CACNA1B (0.57) KCNH2CACNA1BCYP3A4CYP2D6TSHR
SCHEMBL66301 0.94 CACNA1B (0.57) KCNH2CACNA1BCYP3A4CYP2D6TSHR
SCHEMBL65983 0.89 CACNA1B (0.57) KCNH2CACNA1BSCN5AHTR2AADRA1A
SCHEMBL65416 0.85 CACNA1B (0.59) KCNH2CACNA1BCYP3A4CYP2D6TSHR
SCHEMBL67493 0.84 CACNA1B (0.69) KCNH2CACNA1BCYP3A4FAAHCNR1
SCHEMBL66621 0.82 CACNA1B (0.61) KCNH2CACNA1BCYP3A4CYP2D6TSHR
SCHEMBL67097 0.82 CYP3A4 (0.43) KCNH2CACNA1BCYP3A4CYP2D6TSHR
SCHEMBL65481 0.81 CACNA1B (0.63) KCNH2CACNA1BTSHRSLC6A3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129417-B2 Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-03-06 US claimed
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-11-17 US claimed
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-05-27 US claimed
US-8129417-B2 Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-03-06 US disclosed
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-11-17 US disclosed
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, ORAI1, CACNA1S KCNH2 24/4885CACNA1B 5/4885CYP3A4 1006/4885
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, ORAI1, CACNA1S KCNH2 24/4885CACNA1B 5/4885CYP3A4 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.